Larimar Therapeutics Stock (NASDAQ:LRMR)

Forecast Ownership Financials Chart Transcripts

Previous Close

$3.60

52W Range

$2.22 - $6.42

50D Avg

$4.06

200D Avg

$3.99

Market Cap

$296.96M

Avg Vol (3M)

$1.74M

Beta

0.82

Div Yield

-

LRMR Company Profile

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Jun 19, 2014

Website

LRMR Performance

LRMR Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-172.50M	$-90.89M	$-41.76M
Net Income	$-165.67M	$-80.60M	$-36.95M
EBITDA	$-172.50M	$-90.57M	$-41.45M
Basic EPS	-	$-1.32	$-0.84
Diluted EPS	-	$-1.32	$-0.84

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 23Sep 29, 25 | 1:45 PM

Peer Comparison

Ticker	Company
ACIU	AC Immune S.A.
LXEO	Lexeo Therapeutics, Inc. Common Stock
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ANRO	Alto Neuroscience, Inc.
KYTX	Kyverna Therapeutics, Inc.
ENGN	enGene Holdings Inc.
DBVT	DBV Technologies S.A.
AMRN	Amarin Corporation plc
KRRO	Korro Bio, Inc.